.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX21_Elapegademase.Elapegademase .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX21_Elapegademase.Elapegademase| name: | Elapegademase | |
| ATC code: | L03AX21 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 0.4 | mg |
| volume of distribution: | 0.2 | L |
| clearance: | 2.5 | mL/min/kg |
| other parameters in model implementation | ||
Elapegademase (brand name: Revcovi) is a recombinant, pegylated adenosine deaminase enzyme used as enzyme replacement therapy for adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare genetic disorder. It is approved by the FDA and is indicated for use in both pediatric and adult patients with ADA-SCID.
Estimated pharmacokinetic parameters for typical adult patient, as no published sources reporting specific PK parameters (clearance, volume of distribution, etc.) for elapegademase were identified in the literature.